BioMarin Pharmaceutical Welcomes Timothy P. Walbert to Its Board of Directors

BioMarin Pharmaceutical Welcomes Timothy P. Walbert

On February 24, 2025, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced a significant addition to its leadership team with the appointment of Timothy P. Walbert to its Board of Directors. Mr. Walbert, a recognized figure in the biopharmaceutical industry, formerly served as chairman, president, and CEO of Horizon Therapeutics, a company dedicated to addressing rare diseases. His tenure at Horizon spanned from its inception in 2008 until its acquisition by Amgen in 2023, during which he was instrumental in the company's growth and success.

Mr. Walbert brings a wealth of experience to BioMarin, reflecting over 30 years of expertise across various pharmaceutical companies, including Pharmacia, Merck, Pfizer, and Wyeth Ayerst. This extensive background equips him with unparalleled insight into the challenges and opportunities within the biopharmaceutical landscape. In addition to his role at BioMarin, he currently holds board positions at Sagimet Biosciences, Mirum Pharmaceuticals, and Century Therapeutics, further showcasing his commitment to advancing healthcare.

Alexander Hardy, president and CEO of BioMarin, expressed enthusiasm for Mr. Walbert's appointment, stating, "Tim is a deeply talented and well-respected leader with significant operational expertise, who brings a wealth of insight in commercializing medicines." Hardy emphasized that Walbert's addition to the board aligns perfectly with BioMarin's mission of prioritizing patients' needs while ensuring the company's strategies focus effectively on innovation and growth.

In his own words, Mr. Walbert shared his excitement: "I am pleased to join BioMarin's Board as the company works to deliver on the new strategy laid out last year focused on innovation, growth, and value creation." He noted his ongoing commitment to patient-centered healthcare, expressing eagerness to collaborate with the BioMarin team in advancing new treatments for genetically defined conditions.

BioMarin has established itself as a leading biotechnology company, dedicated to transforming genetic discoveries into impactful medicines. Founded in 1997 and based in San Rafael, California, the company is known for its innovative therapeutic solutions targeting rare or complex genetic disorders. With a track record of eight commercial therapies and a robust pipeline of clinical and preclinical candidates, BioMarin is positioned at the forefront of the biopharmaceutical field.

The appointment of Timothy P. Walbert comes at a pivotal time for BioMarin, as the company continues to navigate the complexities of the market while striving to deliver groundbreaking treatments. As the emphasis on personalized medicine and genetics grows, the insights that Mr. Walbert brings will likely prove invaluable in steering BioMarin through upcoming challenges and opportunities.

In conclusion, Mr. Walbert's extensive expertise, dedication to patient welfare, and strategic vision enhance the dynamic leadership structure at BioMarin. The board looks forward to leveraging his experience to drive forward the organization's goals and empower further innovation in the biotech space. Stakeholders and patients alike will undoubtedly benefit from his addition to the team, fostering a commitment to meeting the needs of individuals with rare genetic conditions. As BioMarin advances its mission, the company stands ready to extend its impact through innovative solutions underpinned by robust technological capabilities and a passionate commitment to healthcare excellence.